Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA
Screening Center of Excellence
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) announced today that the Harvard Medical
School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA
Screening Center of Excellence. ICCB-L supports investigators at Harvard Medical School, and
associated hospitals and institutions, for high-throughput screening of small molecule and RNAi
libraries.
Boston, MA and Copenhagen, Denmark (PRWEB) November 30, 2009 -- Exiqon A/S (NASDAQ OMX
Copenhagen: “EXQ”) announced today that the Harvard Medical School ICCB-Longwood Screening Facility
(ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence. ICCB-L supports investigators at
Harvard Medical School, and associated hospitals and institutions, for high-throughput screening of small
molecule and RNAi libraries.
MicroRNAs are a novel class of small, non-coding RNA species, which have been shown to play a major role in
post-transcriptional processing of messenger RNA, including the regulation of many physiological and
pathological processes, such as cellular development, cancer, apoptosis, aging, metabolic diseases, and immune
responses. The external modulation of microRNA expression levels has been shown to have dramatic impact on
cellular phenotype, a result which has promoted the functional analysis of microRNA to the forefront of
translational medicine.
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new
consortium of Harvard-affiliated investigators, coordinated by Dr. Neil Kubica of the Blenis Laboratory at
Harvard Medical School. The consortium has developed multiple biological models that will be interrogated with
the Knockdown Library. The Library contains over 900 specific inhibitors designed for uniform potency, made
possible through the incorporation of Exiqon’s proprietary LNA™ technology.
“My colleagues and I look forward to screening the Knockdown Library. There is a great